GlassScriptPhysician profile
Aaliya Amer
NPI 1518999093
$1,087.21
in general payments reported to CMS, 2019-2025
19 companies · $614 in 2025
The $614 reported for 2025 was more than what 77% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $143 · 2023: $40.62 · 2024: $289 · 2025: $614.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $944.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $944.25 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $367.04 | 2023-2025 | Avycaz, Dalvance |
| Astrazeneca Pharmaceuticals LP | $142.96 | 2022 | |
| Ucb, INC. | $104.20 | 2024-2025 | Bimzelx, Briviact, Nayzilam |
| Averitas Pharma INC. | $53.89 | 2024-2025 | Qutenza |
| Glaxosmithkline, LLC. | $49.26 | 2024-2025 | Arexvy, Shingrix |
| Exact Sciences Corporation | $41.47 | 2025 | Cologuard Collection Kit |
| Amgen INC. | $36.59 | 2024-2025 | Krystexxa, Repatha, Otezla |
| Spr Therapeutics, INC | $32.11 | 2025 | Sprint Pns System |
| Alexion Pharmaceuticals, INC. | $31.90 | 2024 | Strensiq |
| Astellas Pharma US INC | $28.55 | 2024 | Veozah |
| Novartis Pharmaceuticals Corporation | $28.54 | 2024 | |
| Boston Scientific Corporation | $27.63 | 2025 | Watchman Flx |
| Ossur Americas, INC. | $26.59 | 2025 | |
| Horizon Therapeutics Plc | $22.91 | 2023 | Krystexxa |
| Genentech USA, INC. | $22.08 | 2025 | Ocrevus Zunovo |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Life Molecular Imaging LTD | $21.24 | 2025 | Neuraceq |
| Neurocrine Biosciences, INC. | $20.33 | 2025 | |
| Lundbeck LLC | $15.20 | 2025 | Rexulti |
| Pfizer INC. | $14.72 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Aaliya Amer listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.